Optimum chemotherapy for the management of advanced biliary tract cancer

doi:10.3748/wjg.v21.i14.4121

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 14

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10685)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

469

WORD

472

HTML

3640

Tables (1-1)

542

Sum=5123

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

729

Download

1675

Sum=2404

Publishing Process of This Article

Item

Count

Browse

1196

Download

1964

Sum=3160

Apr 14, 2015 (publication date) through Feb 20, 2026

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Gastroenterol. Apr 14, 2015; 21(14): 4121-4125
Published online Apr 14, 2015. doi: 10.3748/wjg.v21.i14.4121

Optimum chemotherapy for the management of advanced biliary tract cancer

Marwan Ghosn, Hampig Raphael Kourie, Elie El Rassy, Ralph Chebib, Fadi El Karak, Colette Hanna, Dolly Nasr

Marwan Ghosn, Hampig Raphael Kourie, Elie El Rassy, Ralph Chebib, Fadi El Karak, Colette Hanna, Dolly Nasr, Department of Oncology, Faculty of Medicine, Saint Joseph University, Beirut 2038 3054, Lebanon

Author contributions: Ghosn M initiated the review; Ghosn M, Kourie HR, El Rassy E performed the review, analyzed the data and wrote first draft; Ghosn M, Kourie HR, El Rassy E, Chebib R, El Karak F, Hanna C and Nasr D reviewed and commented on the paper and provided final approval.

Conflict-of-interest: To the best of our knowledge, no conflict of interest exists.

Correspondence to: Marwan Ghosn, MD, Department of Oncology, Faculty of Medicine, Saint Joseph University, Monot St, Beirut, PO Box 166830, Beirut 2038 3054, Lebanon. mghosn.hdf@usj.edu.lb

Telephone: +961-1-3226842 Fax: +961-1-1613397

Received: November 30, 2014
Peer-review started: November 30, 2014
First decision: December 26, 2014
Revised: January 13, 2015
Accepted: February 13, 2015
Article in press: February 13, 2015
Published online: April 14, 2015
Processing time: 136 Days and 8.8 Hours

Abstract

Biliary tract cancers (BTCs) are highly fatal malignancies, which are often diagnosed at an advanced stage and have relatively poor prognosis. The treatment of patients with advanced BTC is systemic, based on chemotherapy or best supportive care, depending on their performance status. Despite clinical trials studying many chemotherapeutic regimens and targeted therapies for the treatment of BTC, the standard of care for advanced BTC remains the combination of gemcitabine with cisplatin. Many new molecules targeting proliferation and survival pathways, the immune response and angiogenesis are currently undergoing phase I and II trials for the treatment of advanced BTC with promising results.

Keywords: Biliary tract cancer; Chemotherapy; Updates; Treatment modalities; Novel therapies

Core tip: This paper is a recent study outlining the most recent updates on the treatment of advanced biliary tract cancers. After a brief review of the different treatments used for advanced biliary tract cancers, current treatment options, novel therapies and future approaches are discussed.